Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review
Introduction Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment. Case presentation The first case was of a 72‐year‐old woman who underwent robot‐assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. R...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12685 |
| _version_ | 1797280225434796032 |
|---|---|
| author | Kenta Takahashi Renpei Kato Daiki Ikarashi Tomohiko Matsuura Shigekatsu Maekawa Mitsugu Kanehira Ryo Takata Jun Sugimura Takaya Abe Wataru Obara |
| author_facet | Kenta Takahashi Renpei Kato Daiki Ikarashi Tomohiko Matsuura Shigekatsu Maekawa Mitsugu Kanehira Ryo Takata Jun Sugimura Takaya Abe Wataru Obara |
| author_sort | Kenta Takahashi |
| collection | DOAJ |
| description | Introduction Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment. Case presentation The first case was of a 72‐year‐old woman who underwent robot‐assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab–axitinib, continued progression‐free survival was confirmed at the 90‐week follow‐up. The second case was of a 41‐year‐old woman referred to our hospital and presented with translocation renal cell carcinoma metastasis to a para‐aortic lymph node. After treatment with avelumab–axitinib, continued progression‐free survival was confirmed at the 43‐week follow‐up. Conclusion The outcomes of these cases indicate that avelumab–axitinib therapy has a long‐term antitumor effect in some patients with tRCC. |
| first_indexed | 2024-03-07T16:37:06Z |
| format | Article |
| id | doaj.art-1fb457a5a7234ea6b2cc6550f437e6b0 |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-03-07T16:37:06Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-1fb457a5a7234ea6b2cc6550f437e6b02024-03-03T09:26:39ZengWileyIJU Case Reports2577-171X2024-03-017213113510.1002/iju5.12685Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature reviewKenta Takahashi0Renpei Kato1Daiki Ikarashi2Tomohiko Matsuura3Shigekatsu Maekawa4Mitsugu Kanehira5Ryo Takata6Jun Sugimura7Takaya Abe8Wataru Obara9Department of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanDepartment of Urology Iwate Medical University Shiwa‐gun Iwate JapanIntroduction Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment. Case presentation The first case was of a 72‐year‐old woman who underwent robot‐assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab–axitinib, continued progression‐free survival was confirmed at the 90‐week follow‐up. The second case was of a 41‐year‐old woman referred to our hospital and presented with translocation renal cell carcinoma metastasis to a para‐aortic lymph node. After treatment with avelumab–axitinib, continued progression‐free survival was confirmed at the 43‐week follow‐up. Conclusion The outcomes of these cases indicate that avelumab–axitinib therapy has a long‐term antitumor effect in some patients with tRCC.https://doi.org/10.1002/iju5.12685avelumabaxitinibimmune checkpoint inhibitorsrenal cell carcinomatranslocation renal cell carcinoma |
| spellingShingle | Kenta Takahashi Renpei Kato Daiki Ikarashi Tomohiko Matsuura Shigekatsu Maekawa Mitsugu Kanehira Ryo Takata Jun Sugimura Takaya Abe Wataru Obara Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review IJU Case Reports avelumab axitinib immune checkpoint inhibitors renal cell carcinoma translocation renal cell carcinoma |
| title | Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review |
| title_full | Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review |
| title_fullStr | Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review |
| title_full_unstemmed | Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review |
| title_short | Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review |
| title_sort | avelumab plus axitinib for translocation renal cell carcinoma a case series and literature review |
| topic | avelumab axitinib immune checkpoint inhibitors renal cell carcinoma translocation renal cell carcinoma |
| url | https://doi.org/10.1002/iju5.12685 |
| work_keys_str_mv | AT kentatakahashi avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT renpeikato avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT daikiikarashi avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT tomohikomatsuura avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT shigekatsumaekawa avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT mitsugukanehira avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT ryotakata avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT junsugimura avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT takayaabe avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview AT wataruobara avelumabplusaxitinibfortranslocationrenalcellcarcinomaacaseseriesandliteraturereview |